Physician profile
Christopher Robert Lynch
NPI 1447211990
$5,835.61
in general payments reported to CMS, 2019-2025
39 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $349 · 2021: $644 · 2022: $629 · 2023: $858 · 2024: $1,379 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,391.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $717.57 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Medtronic, INC. | $310.12 | 2021-2024 | Nexpowder |
| Regeneron Healthcare Solutions, INC. | $285.72 | 2022-2025 | Dupixent |
| Ambu INC. | $261.19 | 2020-2021 | |
| Covidien Lp | $240.17 | 2019-2020 | |
| Pfizer INC. | $235.32 | 2022-2025 | |
| Gilead Sciences, INC. | $202.78 | 2019-2025 | |
| Janssen Biotech, INC. | $167.88 | 2019-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $165.16 | 2021-2023 | Exalt Model D |
| Madrigal Pharmaceuticals | $157.44 | 2024 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $144.08 | 2023-2025 | |
| Enterra Medical, INC. | $136.32 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.84 | 2019-2020 | |
| Lilly USA, LLC | $126.07 | 2019-2025 | Omvoh |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.